– Reuters
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile For LUMRYZ For Extended-Release Oral Suspension At World Sleep 2023
– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October 24 with